截至2025年8月6日收盘，塞力医疗股价报28.05元，较前一交易日下跌1.45元，跌幅4.92%。当日开盘价 为29.85元，最高触及30.29元，最低下探至27.90元，成交量为38.61万手，成交额达10.99亿元。 塞力医疗属于医药商业板块，公司主营业务涵盖医疗器械、体外诊断产品的研发、生产和销售，同时提 供医疗供应链管理服务。其业务范围涉及医院集约化运营、区域检验中心建设等领域。 8月6日早盘，塞力医疗股价快速回调，5分钟内跌幅超过2%，盘中最低报29.21元。当日主力资金净流 出1.65亿元，近五个交易日累计净流出4.02亿元。 风险提示：股市有风险，投资需谨慎。 来源:金融界 ...

Core Viewpoint - The stock price of Saily Medical closed at 29.50 yuan on August 5, showing a decline of 0.51% compared to the previous trading day, with notable price fluctuations throughout the day [1] Company Overview - Saily Medical's main business includes centralized marketing and service for medical testing, as well as the agency, research, production, and sales of in vitro diagnostic products [1] - The company holds a significant market influence in the medical commercial sector within Hubei province [1] Market Activity - On August 5, the net outflow of main funds was 4.6852 million yuan, with a cumulative net outflow of 276 million yuan over the past five trading days [1] - The trading volume for the day reached 1.055 billion yuan, with a turnover rate of 18.99%, indicating a high level of market activity [1]

证券之星消息，8月4日医药商业板块较上一交易日下跌0.23%，塞力医疗领跌。当日上证指数报收于 3583.31，上涨0.66%。深证成指报收于11041.56，上涨0.46%。医药商业板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 301015 | 目洋医药 | 22.39 | 1.91% | 12.41万 | 2.71亿 | | 603939 | 益丰药房 | 24.60 | 1.61% | 6.75万 | 1.65亿 | | 603233 | 大参林 | 17.58 | 0.92% | 4.67万 | 8141.04万 | | 600511 | 国药股份 | 30.04 | 0.74% | 5.65万 | 1.69亿 | | 603122 | 合富中国 | 7.28 | 0.55% | 6.14万 | 4434.06万 | | 301017 | 漱玉平民 | 13.35 | 0.45% | 6.99万 | 9203.55万 | | 605266 | 健之佳 | 22.0 ...

创新药概念股集体走低，奥翔药业（603229）触及跌停，科兴制药跌超10%，塞力医疗（603716）、德 展健康（000813）、海创药业跌幅居前。 ...

Group 1 - The medical waste treatment sector saw an increase of 1.24% as of the market close on August 1, with a total capital inflow of 15.67 million [1] - A total of 25 stocks in the sector experienced gains, while 4 stocks declined [1] - The top-performing stocks included: Saili Medical (6.2%), Zhongshan Public Utilities (4.26%), Xuelang Environment (4.02%), Donghua Technology (4.0%), and Gangtong Medical (3.41%) [1] Group 2 - The stocks with the largest capital inflow were: Saili Medical with 3.49 million, Zhongshan Public Utilities with 6.48 million, and Xuelang Environment with 4.99 million [1] - The stocks that experienced the largest declines included Huakang Clean (−5.97%), Wanbangda (−0.64%), and Zhonggang International (−0.47%) [1] - The overall market sentiment in the medical waste treatment sector appears positive, with significant capital inflow into several key stocks [1]

Market Performance - As of August 1, the DRG/DIP concept increased by 1.87%, ranking second among concept sectors, with 19 stocks rising, including Saily Medical, Sichuang Medical, and Jiayuan Technology, which rose by 6.20%, 5.04%, and 5.00% respectively [1] - The top-performing concept sectors included Animal Vaccines at 2.22% and BC Batteries at 1.71%, while the worst performers included the China Shipbuilding System at -2.54% and Military Equipment Restructuring at -1.90% [2] Capital Flow - The DRG/DIP concept sector saw a net inflow of 109 million yuan, with 14 stocks receiving net inflows, and 10 stocks exceeding 10 million yuan in net inflow, led by Weining Health with a net inflow of 93.03 million yuan [2] - Other notable net inflows included Saily Medical at 33.50 million yuan, Rongke Technology at 31.92 million yuan, and Sichuang Medical at 30.87 million yuan [2] Stock Performance - The top stocks in the DRG/DIP concept based on net capital inflow included Weining Health with a 3.31% increase and a turnover rate of 9.45%, followed by Saily Medical at 6.20% and a turnover rate of 25.56% [3] - Other significant performers included Rongke Technology at 2.31% and Sichuang Medical at 5.04%, with respective net inflow ratios of 6.05% and 5.47% [3][4]

Group 1 - The medical waste treatment sector saw an increase of 1.61%, ranking 6th among concept sectors, with 32 stocks rising, including Tsinghua Design which hit a 20% limit up [1] - Notable gainers in the sector included Saili Medical, Zhongshan Public Utilities, and Xuelang Environment, which rose by 6.20%, 4.26%, and 4.02% respectively [1] - The sector experienced a net inflow of 164 million yuan from main funds, with 20 stocks receiving net inflows, and 8 stocks exceeding 10 million yuan in net inflow [1] Group 2 - Tsinghua Design led the net inflow with 135.38 million yuan, followed by Saili Medical, Shou Chuang Environmental Protection, and Beijing Capital Co., which received net inflows of 33.50 million yuan, 26.93 million yuan, and 17.87 million yuan respectively [2] - The net inflow ratios for Tsinghua Design, China Tianying, and Tsinghua Environment were 37.14%, 14.94%, and 14.52% respectively [2] - The medical waste treatment sector's performance was contrasted by declines in other sectors, such as the military equipment restructuring concept which fell by 1.90% [1][2]

Core Viewpoint - The stock of Saily Medical experienced a 5.13% increase on August 1, reaching 31.56 yuan per share, with a trading volume of 282 million yuan and a turnover rate of 4.77%, resulting in a total market capitalization of 6.029 billion yuan [1] Company Overview - Saily Medical Technology Group Co., Ltd. is located at 1310 Jinshan Avenue, Dongxihu District, Wuhan. The company primarily operates in the field of medical intensive operation management services and has established partnerships with well-known IVD suppliers both domestically and internationally [1] - The company provides comprehensive supply chain services for in vitro diagnostic products and is further developing information technology to support the construction of an intensive operation service platform. Saily Medical has a deep layout in supply chain information technology, blockchain, and the Internet of Things, maintaining close cooperation with big data and information management system development companies [1] Financial Performance - As of March 31, Saily Medical had 46,600 shareholders, with an average of 4,099 circulating shares per person [1] - For the first quarter of 2025, Saily Medical reported an operating income of 287 million yuan, a year-on-year decrease of 40.75%. The net profit attributable to shareholders was -14.32 million yuan, reflecting a year-on-year decline of 553.66% [1]

Core Viewpoint - The A-share market has seen a strong performance in the biopharmaceutical sector, particularly in vaccine stocks, driven by the release of the 2025 treatment plan for Chikungunya virus, highlighting the lack of available vaccines in China [1][2] Group 1: Market Performance - Shenyuan Biological (申联生物) rose by over 10%, with a year-to-date increase of 42.60% and a market capitalization of 3.203 billion [2] - Global Printing (环球印务) increased by 9.96%, with a market cap of 3.252 billion and a year-to-date rise of 34.04% [2] - Guanhao Biological (冠昊生物) saw a 7.70% increase, with a market cap of 4.969 billion and a year-to-date increase of 55.65% [2] - Sealy Medical (塞力医疗) rose by 5.60%, with a market cap of 6.055 billion and an impressive year-to-date increase of 339.06% [2] - Other notable performers include Kanglao Weishi (康乐卫士) up 4.98%, Jinhai Biological (金河生物) up 4.62%, and Weilan Biological (蔚蓝生物) up 4.41% [1][2] Group 2: Regulatory and Health Measures - The 2025 Chikungunya virus treatment plan emphasizes preventive measures such as eliminating mosquito breeding sites and using repellents [1] - Travelers to Chikungunya endemic areas are advised to enhance their preventive awareness to avoid infection [1] - Currently, there is no available vaccine for the Chikungunya virus in China, indicating a potential market opportunity for vaccine development [1]

Core Viewpoint - The A-share market has seen a strong performance in the biopharmaceutical sector, particularly in vaccine stocks, driven by the release of the 2025 treatment plan for Chikungunya virus, which has heightened awareness and demand for related medical solutions [1][2]. Group 1: Stock Performance - Shenyuan Biological (申联生物) rose by 10.33%, with a market capitalization of 3.203 billion [2] - Global Printing (环球印务) increased by 9.96%, with a market capitalization of 3.252 billion [2] - Guanhao Biological (冠昊生物) saw a rise of 7.70%, with a market capitalization of 4.969 billion [2] - Seer Medical (塞力医疗) grew by 5.60%, with a market capitalization of 6.055 billion [2] - Kanglao Guardian (康乐卫士) increased by 4.98%, with a market capitalization of 4.793 billion [2] - Jinhai Biological (金河生物) rose by 4.62%, with a market capitalization of 5.594 billion [2] - Weilan Biological (蔚蓝生物) increased by 4.41%, with a market capitalization of 3.831 billion [2] - Yongshun Biological (永顺生物) rose by 3.94%, with a market capitalization of 2.742 billion [2] - Dezhan Health (德展健康) increased by 3.51%, with a market capitalization of 10.5 billion [2] - Junzheng Group (君正集团) rose by 3.37%, with a market capitalization of 46.6 billion [2] - Kanghua Biological (康华生物) increased by 3.19%, with a market capitalization of 10.4 billion [2] Group 2: Market Context - The 2025 version of the Chikungunya virus treatment plan emphasizes preventive measures such as eliminating mosquito breeding grounds and using repellents [1] - There is currently no available vaccine for the Chikungunya virus in China, which may drive demand for vaccine development [1] - Free nucleic acid screening for Chikungunya virus is being conducted in Lecong Town, Shunde District, targeting close contacts of confirmed cases [1]